The tumor specific HSP-complexes vaccine named HSP peptide complex-96 (HSPPC-96 or Oncophage® or Prophage, previously Vitespen; Agenus, Lexington, MA, USA) has shown itself capable of inducing MHC I-restricted immune responses in a range of tumor types, and clinical responses in patients with earlier-stage disease, in line with previously published data on cancer vaccines. Here, HSP90B2P is linked to neoplasm.